GlassScriptPhysician profile
Allison R Edwards
NPI 1194821470
$247.04
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67.40 | 2020 | |
| Glaxosmithkline, LLC. | $43.56 | 2020 | |
| Merck Sharp & Dohme LLC | $27.52 | 2020 | |
| Eisai INC. | $23.23 | 2020 | |
| Esperion Therapeutics, INC. | $22.68 | 2020 | |
| Pfizer INC. | $20.98 | 2020 | |
| Gilead Sciences, INC. | $15.60 | 2020 | |
| Allergan, INC. | $14.36 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.71 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.